Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

153 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Validation and clinical performance of a single test, DNA based endometrial cancer molecular classifier.
Jamieson A, Grube M, Kommoss F, Lum A, Leung S, Chiu D, Henderson G, Heitz F, Heublein S, Zeimet AG, Hasenburg A, Diebold J, Walter C, Staebler A, Reynolds J, Lapuk A, McConechy MK, Huntsman DG, Gilks B, Kommoss S, McAlpine JN. Jamieson A, et al. Among authors: kommoss s. Int J Gynecol Cancer. 2024 Oct 26:ijgc-2024-005916. doi: 10.1136/ijgc-2024-005916. Online ahead of print. Int J Gynecol Cancer. 2024. PMID: 39461743
A prospective randomized experimental study to investigate the peritoneal adhesion formation after waterjet injection and argon plasma coagulation (HybridAPC) in a rat model.
Kraemer B, Scharpf M, Keckstein S, Dippon J, Tsaousidis C, Brunecker K, Enderle MD, Neugebauer A, Nuessle D, Fend F, Brucker S, Taran FA, Kommoss S, Rothmund R. Kraemer B, et al. Among authors: kommoss s. Arch Gynecol Obstet. 2018 Apr;297(4):961-967. doi: 10.1007/s00404-018-4661-4. Epub 2018 Jan 23. Arch Gynecol Obstet. 2018. PMID: 29362925
Analysis of risk factors for recurrence in cervical cancer patients after fertility-sparing treatment: The FERTIlity Sparing Surgery retrospective multicenter study.
Slama J, Runnebaum IB, Scambia G, Angeles MA, Bahrehmand K, Kommoss S, Fagotti A, Narducci F, Matylevich O, Holly J, Martinelli F, Koual M, Kopetskyi V, El-Balat A, Corrado G, Căpîlna ME, Schröder W, Novàk Z, Shushkevich A, Fricová L, Cibula D. Slama J, et al. Among authors: kommoss s. Am J Obstet Gynecol. 2023 Apr;228(4):443.e1-443.e10. doi: 10.1016/j.ajog.2022.11.1295. Epub 2022 Nov 23. Am J Obstet Gynecol. 2023. PMID: 36427596
Role of cytoreductive surgery in recurrent ovarian cancer.
Harter P, Hilpert F, Mahner S, Kommoss S, Heitz F, du Bois A. Harter P, et al. Among authors: kommoss s. Expert Rev Anticancer Ther. 2009 Jul;9(7):917-22. doi: 10.1586/era.09.49. Expert Rev Anticancer Ther. 2009. PMID: 19589031 Review.
Molecular characterization of mucinous ovarian tumours supports a stratified treatment approach with HER2 targeting in 19% of carcinomas.
Anglesio MS, Kommoss S, Tolcher MC, Clarke B, Galletta L, Porter H, Damaraju S, Fereday S, Winterhoff BJ, Kalloger SE, Senz J, Yang W, Steed H, Allo G, Ferguson S, Shaw P, Teoman A, Garcia JJ, Schoolmeester JK, Bakkum-Gamez J, Tinker AV, Bowtell DD, Huntsman DG, Gilks CB, McAlpine JN. Anglesio MS, et al. Among authors: kommoss s. J Pathol. 2013 Jan;229(1):111-20. doi: 10.1002/path.4088. J Pathol. 2013. PMID: 22899400
153 results